From modeling to treating Parkinson’s disease:the importance of viral vectors

• Autorzy: Breger L. , Quintino L. , Bjorklund A. , Lundberg C.
• Języki publikacji: EN

Abstrakty

EN

Over the years, viruses have been manipulated and became a common tool in the field of molecular biology. They have played a key role in the development of gene delivery and modulation of gene expression, which are widely used today to model neurodegenerative disorders, in vitro as well as in vivo. With over 6 million people affected worldwide, Parkinson’s disease is the second most common neurodegenerative disorder. It is characterized by a lack of dopamine in the striatum, resulting from neurodegeneration of the substantia nigra. The mechanisms underlying the development of the disease remain unclear and current treatments are only symptomatic. There is therefore a crucial need for the development of more reliable animal models, which better reproduce the disease’s features, including cell loss and protein aggregation. Viral vector can be used to obtain stable expression of causal genes, in various brain regions, thus expending animal modeling beyond genetically engineered mice. Furthermore, gene therapy has been considered as a promising approach for the treatment of neurodegenerative disorders. Different approaches have been studied, from slowing down neuronal death using neurotropic factors to delivering the genes required for dopamine production in the striatum. Whether it is for disease modeling or for therapeutic purposes, gene transfer requires the use of viral vectors. This talk will therefore explore how viral vectors, by taking advantage of the virus properties, have revolutionized Parkinson’s disease research, from disease modeling to therapeutic treatments currently in the clinic.

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2015
• Tom: 75
• Numer: Supl.
• Opis fizyczny: p.S17

Twórcy

autor

Breger L.

• Department of Experimental Medical Science, Wallenberg Neuroscience Centre, Lund, Sweden

autor

Quintino L.

• Department of Experimental Medical Science, Wallenberg Neuroscience Centre, Lund, Sweden

autor

Bjorklund A.

• Department of Experimental Medical Science, Wallenberg Neuroscience Centre, Lund, Sweden

autor

Lundberg C.

• Department of Experimental Medical Science, Wallenberg Neuroscience Centre, Lund, Sweden